ProMetic Life Sciences Inc. | Ownership
Companies that own ProMetic Life Sciences Inc.
The Vanguard Group, Inc.
15,523,176
2.57%
121,070
0%
07/31/2018
Norges Bank Investment Management
4,129,861
0.68%
-6,056
0%
12/31/2017
BMO Asset Management, Inc.
3,067,982
0.51%
-160,270
0%
12/31/2017
BC Investment Management Corp.
2,765,605
0.46%
-474,595
0%
03/31/2017
TD Asset Management, Inc.
2,011,687
0.33%
7,900
0%
12/31/2017
RBC Global Asset Management, Inc.
1,820,500
0.3%
415,900
0%
12/31/2017
Desjardins Global Asset Management, Inc.
1,428,276
0.24%
34,436
0.01%
04/30/2018
TIAA-CREF Investment Management LLC
1,146,454
0.19%
778,341
0%
03/31/2018
Tanaka Capital Management, Inc.
847,934
0.14%
-8,560
0.91%
06/30/2018
Charles Schwab Investment Management, Inc.
746,067
0.12%
0
0%
09/06/2018
| Address |
440 Armand-Frappier Boulevard
Laval Québec H7V 4B4
Canada
|
|
Employees
|
- |
| Website |
http://www.prometic.com |
| Updated |
07/04/2019 |
| Prometic Life Sciences, Inc. engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation, and cancer. It operates through the following segments: Bioseparations, Plasma-derived Therapeutics, and Small Molecule Therapeutics. The Bioseparations segment is involved in large-scale purification of biologics and the elimination of pathogens. |
